Literature DB >> 17505128

Pulmonary hypertension in patients with chronic renal failure.

Y Havlucu1, S Kursat, C Ekmekci, P Celik, S Serter, O Bayturan, G Dinc.   

Abstract

BACKGROUND: Many etiologies causing pulmonary hypertension (PH) have been reported, and one of the background disease seen with patients with PH is chronic renal failure (CRF); however, the pathogenesis of PH in this group of patients is not explained satisfactorily.
OBJECTIVES: The aims of this study were to evaluate the incidence of unexplained PH among patients with CRF and to suggest possible etiologic factors.
METHODS: Two hundred and eleven patients with CRF were evaluated and the ones who have comorbid conditions that cause PH were excluded. Pulmonary arterial pressure (PAP) and cardiac functions were evaluated by Doppler echocardiography. Arteriovenous fistula (AVF) flow was measured by Doppler sonography. The patients were followed for at least 6 months.
RESULTS: Forty-eight CRF patients (20 males, 28 females) were included: 23 were predialysis patients, and 25 patients received hemodialysis via AVF. Patients were followed for 7.5 +/- 1.01 months. Systolic PAP >35 mm Hg was found in 56% (14/25) of patients receiving hemodialysis (36.8 +/- 10.7 mm Hg) and in 39.1% (9/23) of predialysis patients (29.5 +/- 9.5 mm Hg). The parathyroid hormone level, cardiac output values and CRF duration were found to be increased in patients with elevated systolic PAP (p < 0.05). AVF flow and AVF duration were positively correlated with systolic PAP in patients receiving hemodialysis (p < 0.05). There was a negative correlation between systolic PAP and residual urine volume (p < 0.05). AVF compression in hemodialysis patients decreased systolic PAP from 36.8 +/- 10.7 to 32.8 +/- 10.5 mm Hg. Systolic PAP values were increased at the end of the study in the predialysis group, whereas they were decreased at the end of the follow-up in the hemodialysis group (36.9 +/- 10.5 and 32.04 +/- 10.5 mm Hg, respectively).
CONCLUSIONS: This study demonstrates a high incidence of PH among patients with CRF. CRF duration, AVF flow, parathyroid hormone level and cardiac output may be involved in the pathogenesis of PH. The effective hemodialysis and dry weight reduction decreased systolic PAP values. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505128     DOI: 10.1159/000102953

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  33 in total

1.  Pulmonary hypertension as an independent predictor of cardiovascular mortality and events in hemodialysis patients.

Authors:  Zhilian Li; Shuangxin Liu; Xinling Liang; Wenjian Wang; Hongwen Fei; Penghua Hu; Yuanhan Chen; Lixia Xu; Ruizhao Li; Wei Shi
Journal:  Int Urol Nephrol       Date:  2013-06-21       Impact factor: 2.370

2.  Case series of 5 patients with end-stage renal disease with reversible dyspnea, heart failure, and pulmonary hypertension related to arteriovenous dialysis access.

Authors:  Farhan Raza; Mohamad Alkhouli; Frances Rogers; Anjali Vaidya; Paul Forfia
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 3.  Volume Balance and Intradialytic Ultrafiltration Rate in the Hemodialysis Patient.

Authors:  Jason A Chou; Kamyar Kalantar-Zadeh
Journal:  Curr Heart Fail Rep       Date:  2017-10

4.  Pulmonary hypertension in end-stage renal disease and post renal transplantation patients.

Authors:  Esam H Alhamad; Mohammed Al-Ghonaim; Hussam F Alfaleh; Joseph P Cal; Nazmi Said
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

5.  Risk factors for pulmonary hypertension in maintenance hemodialysis patients: a cross-sectional study.

Authors:  Yanjun He; Yuling Wang; Xingying Luo; Jianting Ke; Yi Du; Mi Li
Journal:  Int Urol Nephrol       Date:  2015-11       Impact factor: 2.370

6.  Pulmonary hypertension in an adolescent with end-stage-renal disease-a diagnostic challenge: Answers.

Authors:  Julien Hogan; Rémi Salomon; Saoussen Krid; Damien Bonnet; Antoine Legendre
Journal:  Pediatr Nephrol       Date:  2018-03-12       Impact factor: 3.714

7.  Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD.

Authors:  Sankar D Navaneethan; Jason Roy; Kelvin Tao; Carolyn S Brecklin; Jing Chen; Rajat Deo; John M Flack; Akinlolu O Ojo; Theodore J Plappert; Dominic S Raj; Ghulam Saydain; James H Sondheimer; Ruchi Sood; Susan P Steigerwalt; Raymond R Townsend; Raed A Dweik; Mahboob Rahman
Journal:  J Am Soc Nephrol       Date:  2015-09-18       Impact factor: 10.121

8.  A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance.

Authors:  Kumudha Ramasubbu; Anita Deswal; Cheryl Herdejurgen; David Aguilar; Adaani E Frost
Journal:  Int J Gen Med       Date:  2010-10-05

9.  Pulmonary hypertension in dialysis patients: a cross-sectional italian study.

Authors:  Fabio Fabbian; Stefano Cantelli; Christian Molino; Marco Pala; Carlo Longhini; Francesco Portaluppi
Journal:  Int J Nephrol       Date:  2010-09-30

10.  Presence and outcomes of kidney disease in patients with pulmonary hypertension.

Authors:  Sankar D Navaneethan; Edgard Wehbe; Gustavo A Heresi; Varun Gaur; Omar A Minai; Susana Arrigain; Joseph V Nally; Jesse D Schold; Mahboob Rahman; Raed A Dweik
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.